权益分类	功能权益	普通用户	{{item.name}}会员
{{category.name}}	{{benefitItem.name}}

Elucidating mechanisms for artemisinin-induced dormancy in Plasmodium falciparum

阐明青蒿素诱导恶性疟原虫休眠的机制

基本信息

批准号：
10742385
负责人：
DENNIS E KYLE
金额：
$ 22.65万
依托单位：
UNIVERSITY OF GEORGIA
依托单位国家：
美国
项目类别：
财政年份：
2023
资助国家：
美国
起止时间：
2023-08-16 至 2025-07-31
项目状态：
未结题

来源：
https://reporter.nih.gov/project-details/10742385
关键词：
Antimalarials Artemisinins Bacteria Biological Assay CRISPR/Cas technology Candidate Disease Gene Cells Chromosome 10 Chromosome 13 Circulation Clinical Combined Modality Therapy Complex Copy Number Polymorphism Culicidae Data Development Drug Exposure Drug resistance Erythrocytes Exhibits Exposure to Gene Amplification Genes Growth Half-Life Image In Vitro Infection Investigation Laboratories Link Malaria Malignant Neoplasms Methods Molecular Multi-Drug Resistance Mutation Parasites Patients Pharmaceutical Preparations Pharmacotherapy Phenotype Physiologic pulse Plasmids Plasmodium falciparum Predisposition Probability Process Publishing Recovery Refractory Resistance Resistance development Role Survival Rate Testing Treatment Failure Tuberculosis Work artesunate burden of illness clinically relevant drug discovery effective therapy enhancer-binding protein AP-2 imaging modality novel overexpression pressure prevent resistance mechanism resistant Plasmodium falciparum resistant strain response transmission process treatment duration

项目摘要

Project Summary Among the numerous problems plaguing the malaria elimination efforts is the emergence and spread of drug resistance in P. falciparum. Resistance to artemisinin has led to reduced efficacy of artemisinin combination therapy (ACTs) and ultimately selection of resistance to the partner drugs (e.g., piperaquine). Clearly the threat of multi-drug resistant malaria is as important today as it has ever been, with the precious gains in malaria control threatened by the potential for the spread of P. falciparum strains that are resistant to all currently available treatment drugs. Resistance to artemisinin is not the only factor responsible for treatment failures. Even before artemisinin resistance emerged, recrudescent infections were commonly observed when patients were treated with artemisinin derivatives alone. In some studies, even 5-7 days of treatment with artesunate alone led to ~10% recrudescent infections. The underlying cause of these recrudescent infections has been attributed to the unique ability of artemisinin to arrest the growth of ring stages of P. falciparum. These dormant rings can persist for days to weeks before recovering and growing normally to cause a recrudescent infection. Our published and preliminary data led us to the hypothesis that selection of artemisinin resistance is a two-step process in which the initial responses of the parasite to artemisinin drug pressure is an enhanced dormancy phenotype that confers increased tolerance to drug; subsequently resistance conferring mutations occur (e.g., K13). In Aim 1 we will overexpress genes in a novel chromosome 10 copy number variant we identified in independently derived artemisinin-resistant clones. In Aim 2 will use novel high content imaging assays to quantify enhanced dormancy recovery phenotypes in artemisinin-resistant versus -susceptible P. falciparum. The results of these studies will provide evidence for the molecular basis of recovery from artemisinin-induced dormancy and possibly reveal new mechanisms of resistance to artemisinin.

项目总结